Associated tags: Analysis, Software, Deep learning, Software as a service, Intelligence, Drug design, Artificial intelligence, Drug discovery, Pharmaceutical industry, Health, AI, Research, Biotechnology, Pharmaceutical, Ikto!: 20 Megales Epitihies Tou, Medical Devices, Science, Safety, Clinical Trials
Locations: EUROPE, JAPAN, PARIS, FRANCE, 65 RUE DE PRONY, FR, FRANCE, PARIS, USA, INDIA
Chemistry,
AI,
Intelligence,
Research,
Library,
API,
Drug discovery,
Application,
ChromeOS,
Organization,
Analysis,
Partnership,
Fine chemical Combining the world's largest chemistry database, Reaxys from Elsevier, with cutting-edge AI from Iktos, the advanced platform will enable pharmaceutical companies to identify preclinical drug candidates faster
Key Points:
- The partnership will strengthen Elsevier's flagship chemistry solution, Reaxys , by combining the company's high-quality chemistry data with synthetic planning AI technologies developed by Iktos to accelerate chemistry research for pharmaceutical companies.
- We are delighted to partner with Iktos to bring the valued industry insights that Reaxys offers powered by artificial intelligence, which will help reshape the landscape of small molecule discovery."
- Yann Gaston-Mathé, CEO, Iktos said: "Data is the foundation of AI, and we are very excited to partner with Elsevier.
- The new predictive retrosynthesis and synthetic accessibility tools are based on Iktos' proprietary retrosynthetic technology and trained on Reaxys' reaction database.
Retrieved on:
Wednesday, February 14, 2024
Molecule,
Urology,
Pharmacy,
Doctor of Philosophy,
AI,
Yann,
Saas,
Generative,
Drug design,
Drug discovery,
RIKEN,
Kissei,
Retrosynthetic analysis,
Software as a service,
Astellas Pharma,
Artificial intelligence,
Computational chemistry,
Toyotomi Hideyoshi,
Ono Pharmaceutical,
Pharmaceutical industry Paris (France) and Tokyo (Japan), February 14, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan.
Key Points:
- Paris (France) and Tokyo (Japan), February 14, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan.
- Hideyoshi Fuji has been appointed Representative Director of Iktos K.K., and Vice-President, Japan Business Development and Operations.
- Hideyoshi, 42, spent 13 years at Astellas Pharma Inc. (2009-2021) as an expert in computational chemistry and chemoinformatics.
- After his career with Astellas Pharma, Hideyoshi became an entrepreneur in 2022 and supported business development and marketing efforts in Japan for overseas software companies.
Retrieved on:
Thursday, January 18, 2024
Synthetic media,
Senior,
Diabetes,
DSM-IV codes,
Therapy,
Biology,
Priscilla Chan,
Drug design,
Artificial intelligence,
Kidney,
University,
Business,
Novartis,
AI,
Business development,
Drug discovery,
Generative,
Doctor of Philosophy,
Biomedical Research,
Engineering,
Pharmaceutical industry Paris (France), 18 January, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the appointment of Avirup Bose as Chief Business Officer.
Key Points:
- Paris (France), 18 January, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the appointment of Avirup Bose as Chief Business Officer.
- Avirup Bose holds a PhD in Chemistry from the University of Nebraska, USA, obtained in 1997.
- Avirup Bose, Chief Business Officer of Iktos, comments: "Artificial intelligence is revolutionizing the drug discovery process and I want to be a part of it.
- Yann Gaston-Mathé, co-founder and CEO of Iktos, comments: "We are extremely pleased to welcome Avirup to Iktos as Chief Business Officer.
“We are excited and proud to collaborate with Nerviano Medical Sciences S.r.l, a leading company focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy. In the framework of our collaboration, the NMS team will use Makya, Iktos proprietary Gen AI software in their discovery of a novel candidate drug" said Dr. Quentin Perron, Co-founder and CSO of Iktos. "Indeed, at Iktos, we are committed to developing innovative technologies that enhance the chance of success of small molecule discovery. Our mission is to expedite drug discovery through the application of AI, which we achieve by integrating our robust algorithmic technology, leveraging our expertise from numerous successful collaborations.”--About IktosIncorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, Makya™. Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.
Key Points:
- As per the agreement, NMS will leverage Iktos's expertise in drug design services, with the ultimate goal of identifying at least one promising candidate molecule.
- “We are excited and proud to collaborate with Nerviano Medical Sciences S.r.l, a leading company focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy.
- In the framework of our collaboration, the NMS team will use Makya, Iktos proprietary Gen AI software in their discovery of a novel candidate drug" said Dr. Quentin Perron, Co-founder and CSO of Iktos.
- "Indeed, at Iktos, we are committed to developing innovative technologies that enhance the chance of success of small molecule discovery.
Retrieved on:
Thursday, December 14, 2023
Seed,
Drug design,
Agriculture,
Software,
Deep learning,
Pharmacy,
Farmer,
Software as a service,
Molecule,
Health,
Crop protection,
Artificial intelligence,
Climate change,
Food,
Food security,
Safety,
Environment,
Pharmaceutical industry Makya™ is based on deep learning generative models which design and optimize, in-silico, novel molecules that satisfy multiple parameters, such as efficacy, selectivity, safety, and sustainability.
Key Points:
- Makya™ is based on deep learning generative models which design and optimize, in-silico, novel molecules that satisfy multiple parameters, such as efficacy, selectivity, safety, and sustainability.
- The technology brings new insights and directions into the molecular discovery process based on a comprehensive data-driven chemical structure generation technology.
- “Bayer’s CropKey approach to crop protection innovation is made possible by data-driven breakthrough technologies such as those made accessible by Iktos.
- This way, the promise of AI to dramatically improve discovery will have a better chance to be realized and impact small molecule active ingredient development.”
“We are excited and proud to join forces with Kissei, a leading Japanese pharmaceutical company and to have their scientists use our software in their drug discovery projects", said Yann Gaston-Mathé, Co-founder and CEO of Iktos. “At Iktos, we strive to build an innovative technology platform capable of improving the efficiency of small molecule discovery by combining our powerful algorithmic technology, our know-how derived from the experience of the many collaborations we have established to date, and an intuitive and user-friendly user interface which is essential to an optimal user experience.” --About IktosIncorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry, and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, Makya™. Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis. Iktos has already validated its technology through more than 50 collaborations with pharmaceutical and biotech companies such as Chiesi Group, Galapagos, Janssen, Merck, Teijin, Ono Pharmaceuticals, Pfizer, Servier, UCB...
Key Points:
- Paris, France, July 3, 2023 – Iktos, a company specialized in Artificial Intelligence for new drug design, today announced that Kissei Pharmaceutical Co., Ltd. (“Kissei”), a Japanese pharmaceutical company with approximately 75 years of history, specialized in the field of urology, kidney-dialysis and unmet medical needs, has introduced Makya™, Iktos Software as a Service Platform for AI-driven drug discovery.
- This will enable the rapid and efficient design of new small molecules, leading to an increase in the speed of drug discovery and development.
- "Iktos has cutting-edge AI technology in small molecule drug discovery research, and their focus on further small molecule drug discovery technology development fits well with our strategy."
- “We are excited and proud to join forces with Kissei, a leading Japanese pharmaceutical company and to have their scientists use our software in their drug discovery projects", said Yann Gaston-Mathé, Co-founder and CEO of Iktos.
Technology,
Other Health,
Health,
General Health,
Pharmaceutical,
Health Technology,
Other Science,
Research,
Software,
Artificial Intelligence,
Science,
Nobel Prize,
Nobel Prize in Chemistry,
Probability,
Crystallization,
Cryogenic electron microscopy,
Drug design,
TPP,
Artificial intelligence,
Drug discovery,
AI,
Safety,
Disease,
Fine chemical,
Pharmaceutical industry,
Chemistry Iktos, a company specialized in Artificial Intelligence for new drug design and Curreio, Inc. (Curreio), a Japanese company specializing in structural analysis of biomolecules using cryo-electron microscopy, today announced a collaboration agreement in AI for new drug design.
Key Points:
- Iktos, a company specialized in Artificial Intelligence for new drug design and Curreio, Inc. (Curreio), a Japanese company specializing in structural analysis of biomolecules using cryo-electron microscopy, today announced a collaboration agreement in AI for new drug design.
- This technology enables the structural analysis of difficult protein and protein-supramolecular complexes, thereby expanding the possibilities of drug discovery for these targets.
- We are therefore thrilled to enter into a research collaboration with Curreio, a specialist in structural analysis of biomolecules and to combine our technology platforms to accelerate structure-based drug discovery together", said Yann Gaston-Mathé, Co-founder and CEO of Iktos.
- “We are delighted to announce that we have successfully signed a collaborative research agreement and excited about this collaboration with IKTOS, a company based in France known for its highly advanced AI technology.
Peptide,
Wuhan Institute of Biological Products,
Robotics,
Intelligence,
Antibody,
Janssen,
Merck Group,
Software as a service,
Drug discovery,
Probability,
Drug development,
Series,
Merck,
Switzerland,
Automation,
Medical device,
Pharmaceutical industry,
Teijin,
Pfizer This financing will enable the company to further develop its AI and drug discovery capabilities and expand its existing SaaS software offering, in addition to launching Iktos Robotics; a unique, end-to-end, drug discovery platform which combines artificial intelligence and automation of chemical synthesis to significantly accelerate drug discovery timelines.
Key Points:
- This financing will enable the company to further develop its AI and drug discovery capabilities and expand its existing SaaS software offering, in addition to launching Iktos Robotics; a unique, end-to-end, drug discovery platform which combines artificial intelligence and automation of chemical synthesis to significantly accelerate drug discovery timelines.
- Within the financing Iktos will additionally extend the application of its solutions to biological products (peptides, antibodies, etc.).
- This allows Iktos to be one of the first companies to offer fully integrated drug discovery services to the pharmaceutical industry.
- The artificial intelligence solutions developed by Iktos are aimed to considerably speed up the drug discovery process, while increasing the probability of success of drug candidates reaching clinical development.
Retrieved on:
Wednesday, November 23, 2022
Biotechnology,
Pharmaceutical,
Health,
Artificial Intelligence,
Medical Devices,
Data Management,
Technology,
Other Health,
Malaria,
Workflow,
Drug design,
HPC,
Software,
Probability,
Partnership,
Library,
Machine learning,
Deep learning,
Intelligence,
Analysis,
Software as a service,
AWS,
Artificial intelligence,
Drug discovery,
MMV,
PDP,
Pharmaceutical industry,
Ikto!: 20 Megales Epitihies Tou Iktos, a leader in Artificial Intelligence for new drug design, today announced a collaboration with Medicines for Malaria Venture (MMV), a leading product development partnership (PDP) in the field of antimalarial drug research and development.
Key Points:
- Iktos, a leader in Artificial Intelligence for new drug design, today announced a collaboration with Medicines for Malaria Venture (MMV), a leading product development partnership (PDP) in the field of antimalarial drug research and development.
- Under this collaboration agreement, Iktos will apply its new DockAI technology to expedite the discovery of novel antimalarial drug candidates.
- Iktos DockAI approach will be applied on a therapeutic target previously identified and validated by MMV for anti-malarial drug development.
- At MMV, we believe that the right application of artificial intelligence and machine learning as proposed by Iktos and partners could bolster malaria drug discovery, said Dr. Jeremy Burrows, Vice President, Head of Drug Discovery at MMV.
Biotechnology,
Pharmaceutical,
Health,
Artificial Intelligence,
Medical Devices,
Technology,
Clinical Trials,
Other Technology,
Artificial intelligence,
Intelligence,
Deep learning,
Solution,
Analysis,
AI,
CEO,
Safety,
Technology,
Software,
Software as a service,
Drug design,
Fine chemical,
Ikto!: 20 Megales Epitihies Tou Key Points:
- Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a collaboration with Galapagos, a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, to apply Iktoss generative modelling artificial intelligence (AI) technology in one of Galapagos drug discovery programs.
- Galapagos scientists will benefit from direct access to Makya and Spaya as part of the collaboration.
- Iktoss AI technology, based on deep generative models, helps to bring new insights and directions into the drug discovery process based on a comprehensive data-driven chemical structure generation technology.
- Iktos is also developing Spaya, a synthesis planning software based upon Iktoss proprietary AI technology for retrosynthesis.
